Found 6 matching trials
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia PHASE1 This is a single-arm, single-center, interventional, dose-escalation clinic...
Show More Location
Anhui Provincial Hospital
Learn More & Join Trial
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL PHASE1 CD19-CAR-γδT cell therapy is a cellular immunotherapy targeting CD19 to per...
Show More Location
Biotherapeutic Department of Chinsese PLA Gereral Hospital
Learn More & Join Trial
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia EARLY_PHASE1 This clinical trial aims to investigate the safety, optimal dosage, and eff...
Show More Location
The First Affiliated Hospital of Soochow University
Learn More & Join Trial
Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases PHASE1 This study is a single-arm, intervention, dose-escalation clinical trial to...
Show More Location
Multiple Locations
Learn More & Join Trial
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. PHASE1 This study is an open-label, exploratory, prospective clinical trial with d...
Show More Location
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Learn More & Join Trial
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL PHASE1 This is a single center, prospective, open-label, single-arm, phase 1/2 stu...
Show More Location
School of phamaceutical, Tsinghua University
Learn More & Join Trial